Overexpression of CD133 promotes the phosphorylation of Erk in U87MG human glioblastoma cells

Neuroscience Letters

Volumn 484, Issue 3, 2010, Pages 210-214

  Dong, Lin ^a   Qi, Nan ^b   Ge, Rui Min ^a   Cao, Cui Li ^c   Lan, Feng ^a   Shen, Li ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cell; CD133; Erk; Migration; Proliferation; Signal pathway

Indexed keywords

CD133 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD; BRAIN NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIOBLASTOMA; GLYCOPROTEINS; HEK293 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PEPTIDES; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 77956935369     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.08.057     Document Type: Article

References (22)

1. Bogoyevitch M.A., Court N.W. Counting on mitogen-activated protein kinases-ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 2004, 16:1345-1354.
2. Boivin D., Labbe D., Fontaine N., Lamy S., Beaulieu E., Gingras D., Beliveau R. The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 2009, 48:3998-4007.
3. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
4. Chen D., Shan J., Zhu W.G., Qin J., Gu W. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 2010, 464:624-627.
5. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
6. Ding W., Mouzaki M., You H., Laird J.C., Mato J., Lu S.C., Rountree C.B. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 2009, 49:1277-1286.
7. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008, 15:504-514.
8. Griguer C.E., Oliva C.R., Gobin E., Marcorelles P., Benos D.J., Lancaster J.J., Gillespie G.Y. CD133 is a marker of bioenergetic stress in human glioma. PLoS One 2008, 3:e3655.
9. Horst D., Scheel S.K., Liebmann S., Neumann J., Maatz S., Kirchner T., Jung A. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J. Pathol. 2009, 219:427-434.
10. Kuida K., Boucher D.M. Functions of MAP kinases: insights from gene-targeting studies. J. Biochem. 2004, 135:653-656.
11. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
12. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
13. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
14. Raman M., Cobb M.H. MAP kinase modules: many roads home. Curr. Biol. 2003, 13:R886-R888.
15. Rubinfeld H., Seger R. The ERK cascade: a prototype of MAPK signaling. Mol. Biotechnol. 2005, 31:151-174.
16. Salmaggi A., Boiardi A., Gelati M., Russo A., Calatozzolo C., Ciusani E., Sciacca F.L., Ottolina A., Parati E.A., La Porta C., Alessandri G., Marras C., Croci D., De Rossi M. Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 2006, 54:850-860.
17. Singh S., Dirks P.B. Brain tumor stem cells: identification and concepts. Neurosurg. Clin. N. Am. 2007, 18:31-38.
18. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
19. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
20. Suetsugu A., Nagaki M., Aoki H., Motohashi T., Kunisada T., Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006, 351:820-824.
21. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., Jiang G., Ge C., Xie H., Wan D., Yang S., Zheng S., Gu J. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 2007, 120:1444-1450.
22. Zhao W.Q., Alkon D.L., Ma W. c-Src protein tyrosine kinase activity is required for muscarinic receptor-mediated DNA synthesis and neurogenesis via ERK1/2 and c-AMP-responsive element-binding protein signaling in neural precursor cells. J. Neurosci. Res. 2003, 72:334-342.